Myelin News and Research

RSS

Myelin is the fatty substance that covers and protects nerves.

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).

26 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

StemCells provides update on PMD Phase I clinical trial

StemCells, Inc. today provided an update on its ongoing Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD), a fatal myelination disorder that afflicts male children.

8 Oct 2010

MRF explores ways to accelerate medical research with online gaming technology

The Myelin Repair Foundation (MRF), a non-profit medical research foundation known for its pioneering Accelerated Research Collaboration (ARC) model, is taking a lesson from online game developers to explore creative ways to accelerate the pace of medical research and shorten the time to market for new medicines.

6 Oct 2010

Smoking increases multiple sclerosis progression: Report

Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals.

27 Sep 2010

Scientists uncover alternative source for damage associated with MS

Scientists have uncovered an alternative source for some of the damage associated with multiple sclerosis, an incurable neuroinflammatory disorder. The research, published online by Cell Press on September 23rd in the journal Immunity, reveals a direct interaction between immune cells and neurons that plays a significant role in neuronal injury and may respond to therapeutic intervention.

24 Sep 2010

Immune-mediated disturbances of neurons contribute to MS: Research

Researchers in Germany have gained new insight into how the immune system causes damage associated with multiple sclerosis (MS), an incurable neuroinflammatory disorder.

24 Sep 2010

Researchers discover generation of pyramidal neurons by glial cell precursors

In an unanticipated finding, researchers at the UC Davis School of Medicine have discovered that, during early adulthood, the brain produces new excitatory neurons, and that these neurons arise from non-neuronal support cells in an area of the brain that processes smell.

10 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

British, Austrian scientists awarded K. J. Zülch Prize for basic neurological research

British and Austrian scientists receive award for basic neurological research. Alastair Compston and Hans Lassmann are this year's recipients of the K. J. Zülch Prize for basic neurological research. In bestowing this award, the Gertrud Reemtsma Foundation is honouring two scientists who have made crucial contributions to research on multiple sclerosis. Alastair Compston's work has provided important insights into the genetics and treatment of multiple sclerosis.

7 Sep 2010

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

A research clinic for multiple sclerosis patients is being set up with a -10 million donation from the author J K Rowling.The Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh will place patients at the heart of research to improve outcomes for multiple sclerosis sufferers.

2 Sep 2010

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

30 Aug 2010

Researchers develop genetically mutated stem cells for myelin research

Vanishing White Matter (VWM) disease is a devastating condition that involves the destruction of brain myelin due to a mutation in a central factor. To understand the disease and test potential treatments that could apply to other disorders, such as multiple sclerosis, Prof. Orna Elroy-Stein of Tel Aviv University's Department of Cell Research and Immunology is leading a scientific breakthrough by developing laboratory mice which carry the VWM mutation an important new tool.

18 Aug 2010

Myelin News and Research

Further Reading

IBEC researchers discover new group of interacting partners for myelin-associated receptors

Top 10 Medical Innovations for 2011

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Salk discovers potential new target for MS

Scientists discover new cell that may limit inflammation in CNS

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

StemCells provides update on PMD Phase I clinical trial

MRF explores ways to accelerate medical research with online gaming technology

Smoking increases multiple sclerosis progression: Report

Scientists uncover alternative source for damage associated with MS

Immune-mediated disturbances of neurons contribute to MS: Research

Researchers discover generation of pyramidal neurons by glial cell precursors

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

British, Austrian scientists awarded K. J. Zülch Prize for basic neurological research

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Researchers develop genetically mutated stem cells for myelin research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News